130P COM701 ± nivolumab: Preliminary results of antitumor activity from a phase I study in patients with metastatic NSCLC who have received prior PD-1/PD-L1 inhibitor

Saved in:
Bibliographic Details
Published in:Immuno-oncology technology 2022-12, Vol.16, p.100242, Article 100242
Main Authors: Sullivan, R.J., Sharma, M.R., Vaena, D., Hamilton, E., Izar, B., Rasco, D., Gainor, J., D. Shepard, Papadopoulos, K., Dumbrava, E.E., Adewoye, H.H., Ferre, P.J., Ophir, E., Patel, M., Patnaik, A., Chmielowski, B.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:2590-0188
2590-0188
DOI:10.1016/j.iotech.2022.100242